Taligen Pipeline Candidates Highlighted at XXIII International Complement Workshop

Novel Biologics Demonstrate Targeting of Complement System to Treat Genetic Disease, Ocular Disease and Organ Transplant

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Taligen Therapeutics, a biotechnology company developing therapies that regulate the complement system to treat inflammatory and immune diseases, today announced that preclinical data on three of its pipeline candidates will be highlighted at the XXIII International Complement Workshop (ICW) taking place August 1-5, 2010, in New York City. During the meeting, preclinical data on Taligen’s drug candidates, TT30, TT32 and TT33, will be presented, demonstrating the company’s progress in generating an emerging product pipeline in multiple therapeutic areas including paroxysmal nocturnal hemoglobinuria (PNH), age-related macular degeneration (AMD) and organ transplant.

“The body of data presented by Taligen at the ICW meeting demonstrate our leadership in translating complement biology and developing a pipeline of targeted therapies with the potential to prevent the severe tissue damage that occurs in a range of diseases, including rare and genetically-driven diseases such as PNH, as well as broader immune system-based conditions such as AMD and organ transplant,” said Abbie Celniker, Ph.D., President and CEO of Taligen. “We expect to make further progress toward clinical development with our novel therapies and proprietary technology platform, driving several product candidates forward internally in certain rare diseases and collaborating with partners for broader disease indications.”

“The results of our many years of work in the complement field are now becoming evident, leading to a range of drug candidates, including those with data presented at this year’s ICW meeting,“ said Michael Holers, M.D., chief scientific officer of Taligen. “We are honored to have several oral presentations and posters of data on Taligen’s product candidates at this meeting, as this conference brings together the preeminent scientific leaders in the field of complement biology.”

Presentations on Taligen’s product candidates at the International Complement Workshop include:

TT30 in the rare genetic disease Paroxysmal Nocturnal Hemoglobinuria (PNH):

  • Oral presentation, Targeted Therapies/Inhibitors, Abstract #14, “The human complement receptor type 2/factor H fusion protein TT30, an alternative pathway specific complement inhibitor, prevents hemolysis of erythrocytes from patients with paroxysmal nocturnal hemoglobinuria by membrane-targeting of factor H activity”, Risitano, et.al, Thursday, August 5, 2010, 10:45am, Grand Hyatt.

TT32 in Heart Transplant:

  • Oral presentation, Targeted Therapies/Inhibitors, Abstract #11, “Targeted complement inhibition significantly ameliorates ischemia reperfusion induced isograft inflammation in a murine model of cardiac transplantation”, Atkinson, et.al, Thursday, August 5, 2010, 10:00am, Grand Hyatt.

TT33 in Liver Transplant:

  • Oral presentation, Targeted Therapies/Inhibitors, Abstract #126, “The terminal pathway of complement in hepatic ischemia/reperfusion injury and regeneration”, Morris, et.al, Thursday, August 5, 2010, 10:15am, Grand Hyatt.

Macular Degeneration

  • Poster, Macular Degeneration, Abstract #LB8, Board #18, “The alternative pathway is required but not sufficient for pathology in mouse laser-induced choroidal neovascularization,” Rohrer, et.al, August 5, 2010, 8:00-9:00am, Grand Hyatt

About Taligen Therapeutics

Taligen Therapeutics is a biotechnology company pioneering a new approach to treating inflammatory and immune diseases by regulating the complement system, a potent and ubiquitous immune pathway. Based on new insights and unique proprietary technology related to complement biology, Taligen is building a deep product candidate pipeline of novel protein therapeutics which selectively identify, target and concentrate on inflammatory tissues. Taligen’s targeted drugs have been shown to naturally and broadly control aberrant inflammation in a broad array of genetic, orphan and large market diseases. Founded in 2004, Taligen Therapeutics maintains its headquarters in Cambridge, Massachusetts. For additional information about the Company, please visit www.taligentherapeutics.com.



CONTACT:

The Yates Network
Gina Nugent, 617-460-3579

KEYWORDS:   United States  North America  Massachusetts

INDUSTRY KEYWORDS:   Health  Biotechnology  Genetics  Hospitals  Medical Devices  Pharmaceutical  Research  Other Science  Medical Supplies  Science

MEDIA:

Suggested Articles

Xcovery's ALK inhibitor shrank tumors in 75% of lung cancer patients, compared to 67% for Pfizer's Xalkori, the first FDA-approved drug of that class.

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.